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ABSTRACT 
Quantifying Structural and Functional Changes in Cardiac Cells  




Diabetes Mellitus is one of the most common diseases in the world. Cardiovascular 
diseases account for ~80% of deaths amongst diabetic patients, primarily through coronary artery 
disease (CAD). However, a new clinical entry, termed Diabetic Cardiomyopathy (DC), may lead 
to heart failure in diabetic patients independently of CAD or hypertension. In DC, hyperglycemia 
and hyperlipidemia associated with diabetes produce structural and biochemical alterations at the 
cardiac cell level. Early stage cell alterations include hypertrophy, calcium mishandling, cell 
apoptosis, excessive ROS production, and increased collagen production by fibroblasts. 
Eventually, major structural and functional changes can appear in myocardial tissue, 
characterized by diastolic and systolic dysfunction, and eventually heart failure. While specific 
changes associated with DC are well characterized, the mechanism underlying disease 
development and progression as a whole remain to be elucidated. The ability of researchers to 
develop general treatment options for this disease is thus limited. 
Currently, a majority of DC studies focus on either in vitro molecular pathways, or in 
vivo whole-heart properties such as ejection fraction. However, as DC is primarily a disease of 
changes in structural and functional properties, these studies can not precisely quantify what 
conditions (such as hyperglycemia and hyperlipidemia) are producing specific biomechanical 
changes such as increased myocardial stiffness or diastolic dysfunction. To address this, we 
 
developed an in vitro approach, based on culturing cardiac cells in elevated glucose and fatty 
acid, to examine how structural and functional properties may change as a result of a diabetic 
environment.  
Increased myocardial stiffness is associated with increased collagen production in the 
heart. However, diastolic dysfunction is found to occur in DC prior to significant collagen 
accumulation. We hypothesized that increased cardiac cell stiffness could contribute to early 
stage diastolic dysfunction. To test this hypothesis, we developed and used contemporary 
biomedical engineering tools to characterize the biomechanical properties of cardiac myocytes 
and fibroblasts under a variety of hyperglycemic and hyperlipidemic conditions. We showed that 
our in vitro model of DC exhibits increased stiffness in myocytes, but not fibroblasts. 
We then developed an assay to measure cardiac myocyte contractile force, as well as 
assess systolic and diastolic function. This assay was then used to determine the role of N-acetyl-
cysteine (NAC), towards regulating reactive oxygen species (ROS) and reversing cellular-level 
changes associated with our DC model. We found that DC model cardiac myocytes exhibited 
greater incidences of diastolic, but not systolic, dysfunction, and that treatment with NAC 
reduced dysfunction to a normal level. In terms of structural properties, we additionally 
determined that treatment with NAC attenuated increases in myocyte stiffness found in our DC 
model, and that NAC reduced myocyte hypertrophy for certain diabetic conditions. Overall, 
treatment with NAC attenuates the maladaptive mechanical and functional changes found in our 
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Chapter 1. Overview 
1.1 General background 
1.1.1 Overview of Diabetic Cardiomyopathy 
Diabetes mellitus (DM) is one of the most common chronic diseases in the world. It is 
estimated that there will be 300 million people with DM by 2050 1. In type 1 DM, autoimmune 
destruction of insulin-producing pancreatic beta cells leads to increased blood glucose 
(hyperglycemia). In type 2 DM, hyperglycemia is caused by insulin resistance and deficiency at 
the cell level, and is generally associated with poor diet and obesity. Type 2 DM accounts for 
90% of diabetes cases, and can be managed to some extent through diet modification and 
exercise 2, 3. Type 1 DM can only be managed through insulin treatment that must be continued 
through the lifespan of the patient. In both cases, symptoms of diabetes include frequent 
urination, increased thirst, increased hunger, and weight loss. 
  Cardiovascular diseases, particularly coronary artery disease (CAD), account for 
approximately 80% of deaths amongst diabetic patients 4. A new disease category, termed 
Diabetic Cardiomyopathy, produces heart failure (HF) in diabetic patients without evidence of 
hypertension or CAD 5. Currently, few studies have measured the prevalence of Diabetic 
Cardiomyopathy on a population level. In one small study of 100 diabetic patients, Diabetic 
Cardiomyopathy was present in 48% 6. Additionally, a study of over 2000 people aged 45 or 
above indicated that DC was present in 1.1% of the entire population 7. 
Diabetic Cardiomyopathy (DC) is defined by alterations in myocardial structure, 
manifesting mainly as left ventricular hypertrophy, and diastolic and systolic dysfunction 8-10.  In 
diabetic patients, diastolic dysfunction is generally defined by a reduction in cardiac relaxation 
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rate, which can also manifest in increased left ventricle end-diastolic pressure (LVDP) and 
increased late mitral flow velocity 11,12. Systolic dysfunction is generally defined clinically as an 
impairment in the ability for the heart to eject blood, which is commonly measured via left 
ventricle ejection fraction 13. 
The current hypothesis regarding DC pathogenesis is that cellular-level alterations 
produce structural and functional changes in the myocardium, which eventually manifest 
themselves in dysfunction 14, 15. These alterations include increased collagen deposition by 
cardiac fibroblasts 16-18, perturbations in myocardial contraction/relaxation coupling 19, cell 
hypertrophy, and apoptosis 20, 21.  
1.1.2 Diabetic Cardiomyopathy pathogenesis 
Early-stage pathogenesis of DC is currently not well understood. While many of the signs 
or symptoms of DC have been found, the actual mechanisms underlying disease progression is 
not well established. This is particularly true in regards to determining the degree to which each 
factor associated with DC contributes to its progression. This lack of understanding contributes 
to the slow development of therapeutic options for DC.  
The diabetic environment is characterized by hyperglycemia and hyperlipidemia, all of 
which produce an array of inter-connected effects in the cardiovascular system. Chronic 
hyperglycemia, as associated with DM, is generally caused by low insulin levels (Type 1 DM) or 
improper insulin handling (Type 2 DM), and is involved in almost all aspects of DC 
pathogenesis, including apoptosis, fibrosis, and myocardial dysfunction 22-24. This reduction in 
insulin action in the myocardium also leads to a metabolic switch from glucose to free-fatty acids 
uptake 25, 26. This increased reliance of the myocardium on free-fatty acids as its fuel source, in 
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combination with the hyperlipidemia commonly found in DM, can damage the mitochondria, 
impair calcium-handing, and induce cell death 25. 
The earliest clinical manifestations of diabetes-induced cardiac dysfunction are increased 
LV stiffness and dysfunctional cardiac relaxation. Hyperglycemia induces cardiac dysfunction 
(as measured by increased left ventricular developed pressure and reduced rates of diastole and 
systole) in diabetic mice 27. These findings closely mirror what is found in DC patients. Diastolic, 
and eventually systolic dysfunction are caused via multiple pathways including PKCBeta2 
activation, increased ROS production, disturbed calcium handling, and myocardial fibrosis 28, 29.  
Myocardial fibrosis is associated with myocyte death (through both apoptosis and 
necrosis) as fibrotic tissue replaces dead cells in the tissue. Additionally, diabetic conditions have 
been found to increase collagen production by fibroblasts 30, 31.  These structural changes 
contribute to an increase in myocardial stiffness, and are believed to contribute initially to 
diastolic dysfunction, but also to systolic dysfunction in later stages of DC 32-35.  
Other major contributors to cell-level contractile dysfunction are oxidative stress and 
impaired calcium handling. Oxidative stress can be caused by over-production of reactive 
oxidative species (ROS) 36, 37. This elevation of ROS can lead to cellular damage by oxidation, 
by interfering with nitric oxide (NO), and by modulating the redox signaling pathways 37. 
Oxidative stress is implicated in all stages of DC, including hypertrophy, fibrosis, and contractile 
dysfunction 38.  Impaired calcium handling is another hallmark of DC, where hyperglycemia and 
hyperlipidemia produce calcium overload in the cytosol, thereby impairing relaxation 39. 
Additionally, hyperglycemia induces apoptosis in cardiac cells both in vitro and in vivo, 
at least partly through activation of the mitochondrial cytochrome c-activated caspase-3 pathway 
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24. Other likely contributors to hyperglycemia-induced apoptosis include Rac1 and excessive 
production of angiotensin II 40, 41. 
While the pathogenesis described here is currently associated with DC, hyperglycemia 
and hyperlipidemia can also contribute to myocardial dysfunction and heart failure even when 
CAD and hypertension are present 42. This means that while the prevalence of DC is currently 
not well established, the mechanism of DC is relevant to all diabetic patients. Therefore, 
clarifying the early stage pathogenesis of DC is crucial for understanding all diabetes related 
heart failure pathogeneses as well as for developing therapeutic strategies for all diabetic patients 
at risk for cardiovascular disease. 
1.1.3 Treatment options for Diabetic Cardiomyopathy 
Some major potential treatment options for DC include beta-blockers, calcium channel 
blockers, and antioxidants. Currently, beta-blockers are commonly used to treat general heart 
failure cases. While there are concerns that beta-blockers may promote insulin resistance and 
hypoglycemia in diabetic patients, these concerns are outweighed by recent research, which 
showed significant survival benefit in diabetic heart failure patients that have been treated with 
beta-blockers 43. Calcium channel blockers reduce the level of calcium found in the cytosol. In 
vivo studies showed that treatment with the calcium channel blocker verapamil significantly 
improved contractile and relaxation rate and left ventricle diastolic pressure (LVDP) in diabetic 
rodents 44, 45. However, there have been no clinical trials on DC patients to determine if calcium 
channel blockers provide benefits in humans. 
Antioxidants may provide an alternative treatment for DC patients. One study showed 
that the antioxidant vitamin E did not provide any cardiovascular benefits to patients with 
diabetes who were at risk for heart failure 46. However, other antioxidants that have shown 
 
 5 
promising results in in vitro and in vivo data but have not been tried in clinical trials for DC 
include N-acetylcysteine (NAC) 47, Tempol 48 and Metallothionen 49. NAC is an especially 
attractive therapeutic option, as it has been shown to provide cardiac-specific benefits, as well as 
prevent hyperglycemia-induced insulin resistance in in vitro and in vivo studies 47, 50. 
1.1.4 In vitro models of Diabetic Cardiomyopathy 
In vitro models of DC generally focus on the effects of hyperglycemia (and to a lesser 
extent hyperlipidemia) on the biochemical processes of cardiac cells, such as the effects of both 
high glucose and high fatty-acids on apoptosis, calcium signaling, and ROS 24, 47, 51. However, 
these studies don’t directly measure structural and functional changes, which are the main 
hallmarks of DC and lead to reduction in cardiac function and heart failure. The major benefit of 
using an in vitro model to study DC is it allows for the measurement of cell biomechanical 
response to a single factor. To deepen our understanding of early stage DC pathogenesis, it is 
crucial to precisely determine what particular diabetic factors (such as high glucose or high fatty-
acid) contribute to specific changes in cardiac cell biomechanics.  
 In terms of the mechanical properties, a stiffening of the myocardium is believed to 
contribute to the appearance of diastolic and eventually systolic dysfunction found in vivo. 
Generally, this increase in stiffness in associated with increased collagen production in the heart 
21,22. However, this increase in collagen production only becomes significant at middle and later 
stages of the disease, while minor diastolic dysfunction is found to occur at an earlier stage 52. As 
the contribution of increased collagen production to dysfunction is unknown at this early stage, 
we explore an alterative hypothesis that diabetic conditions increase cardiac cell stiffness, 
possibly contributing to dysfunction at an early (and possibly later) stage. As the early stage 
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pathogenesis of DC is still not well understood, this study would clarify the progression of 
myocyardial stiffness in DC, as well as open up the possibility of new theraupetic targets. 
On the functional side, the diabetic environment produces oxidative damage and impaired 
calcium handling on the cellular level, which is believed to contribute to diastolic and systolic 
dysfunction. Currently, most research on diabetic cardiac function focuses on either the 
molecular / pathway level pathogenesis or on the whole-heart functional properties such as 
ejection fraction or contraction / relaxation rate. An in vitro biomechanics model of DC can 
provide a middle ground, where it is possible to directly link various diabetic factors with 
dysfunction, as well as quickly assess the efficacy of various treatment options in reducing 
dysfunction. Currently, it is not well understood how factors such as hyperglycemia and 
hyperlipidemia directly affect these functional properties. An in vitro model of cell contraction 
and dysfunction would allow us to quickly and inexpensively quantify these changes as well as 
assess treatment options. 
There are currently numerous methods for measuring the biomechanical properties of 
cells (and cardiac cells in particular).  
1.1.5 Methods for measuring cardiac cell mechanical properties 
The mechanical properties of cells are generally assessed in terms of their viscoelastic 
properties such as stiffness and viscosity. Many techniques have been developed that can 
measure these properties both within the cell’s cytoplasm and at the surface. Optical traps use 
lasers directed at microscopic objects (such as probes or organelles), in order to apply a force on 
the surface or interior of a cell. Force is generated via laser refraction within the bead as well as 
differences in photon density between the laser center and edge 53-55. Similarly, magnetic probes 
can be embedded inside of a cell or attached to the cell surface, where a magnetic linear or 
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twisting force can be applied to the probe. For both optical and magnetic trap experiments, it is 
possible to control the force applied to the object and measure its displacement inside of (or on 
the surface of) the cell 56-58. This force-displacement profile can then be used to estimate cellular 
mechanical properties based on models. Both these techniques require the use of an applied force 
to obtain mechanical properties. This renders the results somewhat ambiguous, as it can be 
difficult to differentiate between passive mechanical properties and the cell’s active response to 
the force.  
Atomic force microscopy (AFM) is a technique wherein a laser is used to track the 
movement of a flexible cantilever as a probe attached to the tip of the cantilever interacts with a 
cell 59-63. The actuator of the AFM cantilever is a piezoelectric ceramic, which changes size in 
response to an applied voltage. The elastic modulus can then be extracted from the force-
deflection relationship of the cantilever, using an adaptation of the Hertz contact model 64. 
Similar to the trapping methods, AFM requires a direct application of force to the cell in order to 
measure stiffness. 
Particle tracking microrheology (PTM) is a passive or active spatiotemporal technique used 
to probe local viscoelastic properties of a wide range of cells types under a variety of conditions 
65-74. In passive PTM, probes are introduced to the cell cytoplasm, where the probes are then 
imaged using fluorescent wide-field microscopy. These probes’ displacements are then tracked 
over time, and the trajectories are used to calculate the storage (representing solid properties) and 
loss (representing fluid properties) modulus of the cytoplasm using mathematical models, such 
as the generalized Stokes-Einstein relation 75.  
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1.1.6 Methods for measuring the functional properties of cardiac myocytes 
While cardiac myocyte functional properties can be defined in many different ways, in 
this study we are specifically referring to contractile force as well as the presence of dysfunction. 
There are currently multiple techniques for measuring the functional or contractile properties of 
cardiac myocytes. One method involves plating myocytes on top of a flexible substrate such as a 
polyacrylamide gel or an array of micropillars 76-79. In the former technique, myocytes are plated 
on polyacrylamide gels embedded with fluorescent beads. The motion of the beads under the cell 
is then tracked during contraction, which can then be used to calculate the force that the cell is 
applying to the substrate. In the latter technique, myocytes are plated on PDMS array of 
micropillars, where the deflection of the pillars can be measured and converted to force through a 
modified beam equation. The benefit of these methods is that they allow for the tuning of the 
mechanical properties of the substrate. Similar to the micropillar array method, another method 
involves the fabrications of much larger pillars where myocytes are plated so that each end 
attaches to the side of a pillar. The contraction force and profile can then be defined by 
measuring the displacement of the two pillars as the myocytes contract 80. 
In terms of measuring the contractile pattern of myocytes (without measuring force) many 
groups employ a technique where the edges of the cells are tracked during contraction 81-83. A 
method that employs this technique to directly measure contractile force involves attaching a 
magnetic bead to the end of the myocyte 82. This technique calculates the contractile force, by 




1.2 Specific aims and organization 
1.2.1 Specific aims 
To guide our efforts, the following specific aims and hypotheses were proposed: 
 
Aim 1: Determine whether diabetic conditions alter cardiac cell mechanical properties in 
terms of stiffness and viscosity. 
Hypothesis: A diabetic environment will lead to an increased stiffness in cardiac cells, 
contributing to early stage increase in myocardial stiffness. 
 
Aim 2: Assess changes in contractile force and dysfunction of cardiac myocytes in an in 
vitro model of Diabetic Cardiomyopathy. 
Hypothesis: A diabetic environment will produce significant changes in the functional properties 




The framework of this thesis consists of three major concentrations: (1) the measurement 
of mechanical properties of neonatal cardiac cells (myocytes and fibroblasts) plated in 
monolayers and in a more physiologic bilayer constructs in a diabetic (high glucose or high fatty-
acid) environment, (2) assessing the functional properties of diabetic myocytes in terms of 
contractile strength and dysfunction, and (3) the assessment of antioxidant therapy for 
modulating maladaptive structural and functional changes in DC. 
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Chapter 2 focused on measuring the mechanical properties of cardiac cells treated with 
high glucose or high fatty acid media. We used both AFM and PTM to measure the mechanical 
properties of normal and DC model cardiac cells in monolayers. To measure the mechanical 
properties of normal and DC model cardiac bilayers (fibroblast plated on top of myocytes), we 
developed an optical sectioning technique to reduce the contribution of out-of-plane data to our 
PTM measurements of both layers. 
Chapter 3 focused on measuring the functional properties of myocytes treated with high 
glucose and high fatty acid media. Specifically, we measure contractile force and assess for 
dysfunction by plating myocytes on micropillars. We additionally investigate the use of N-
acetylecysteine (NAC) for modulating the structural and functional changes found in diabetic 
cardiac cells. 
Chapter 4 presents a summary of this thesis work and discussions of future studies related 









Chapter 2. Quantifying the Mechanical Properties of Cardiac Cells in an in vitro Model of 
Diabetic Cardiomyopathy 
2.1 Introduction 
Study of cardiac cells (myocytes and fibroblasts) can provide valuable information about 
the early-stage pathology of DC. In vivo cardiac cells experience a complex set of physical and 
biochemical stimuli, making it difficult to parse out individual mechanisms in the various clinical 
manifestations of the disease. In vitro experiments allow for the quantification of biomechanical 
and chemical responses to precisely controlled physical and chemical stimuli. This allows for a 
more precise determination of the early pathology of a disease process. While some studies have 
focused on individual cardiac cells in DC-based experiments, these studies generally focus on 
pathway level studies on individual DC markers such as apoptosis and ROS production 84, 85.  
Conversely, there has been little research on quantifying the biomechanical properties, 
such as cell stiffness, of cardiac cells in response to diabetic conditions such as increased glucose 
and free fatty acid concentrations. Changes in cell stiffness can have a significant effect on 
functional properties of cells, such as contractile force 86, 87 and resistance to shear and normal 
forces 88. Additionally, DC is commonly associated with an increase in myocardial stiffness, 
which also contributes to diastolic and systolic dysfunction. However, the mechanism by which 
diabetes produces biomechanical changes is not well understood, especially at an early stage. 
While the current hypothesis suggests that increased collagen production leads to increased 
myocardial stiffness 14, 15, mild diastolic dysfunction is found to occur prior to significant 
collagen production 52. As changes in myocardial stiffness have been shown to contribute to 
diastolic (and eventually systolic) dysfunction, we hypothesize that diabetic conditions directly 
alter cardiac cell stiffness, thereby potentially contributing to early-stage diastolic dysfunction. 
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In addition to measuring the mechanical properties of normal and diabetic cardiac cells 
plated in monolayers, we additionally wished to measure their properties in more physiologic 
fibroblast / myocyte bilayers. The heart is a complex myogenic organ, with a structure consisting 
of cardiac myocytes, fibroblasts, and endothelial cells. By only measuring the mechanical 
properties of cell monolayers, it is possible to discount the impact of structural and biochemical 
interactions on mechanical properties of each of the cell types. Additionally, the myocyte / 
fibroblast bilayer model can better mimic the layered nature of the myocardium. While it is also 
possible to measure the mechanical properties of a co-cultured monolayer, we found that this led 
to groupings of the different cell types, thereby limiting the applicability of the model.  To 
measure the mechanical properties of cardiac cell bilayers, we employ PTM, which allows for 
passive tracking of beads embedded in a cell, to calculate the frequency dependent viscoelastic 
properties of the cell. As this technique does not require direct contact with the cell, it is possible 
to measure cell mechanics in more complex culture scenarios (such as bilayers or embedded in a 
three-dimensional matrix or potentially even in vivo). Additionally, the passive nature of PTM 
allows for the measurement of cell mechanical properties without stimulating the cell (which is 
required for AFM, magnetic bead pulling, and optical trapping) as well as the ability to measure 
frequency-dependent properties simultaneously (as opposed to other methods which require the 
measurement at different frequencies in series). 
One drawback of PTM is that as it generally requires the tracking of bright fluorescent 
probes, out-of-plane data can introduce significant errors in the measurement of mechanical 
properties. This is especially crucial in cell bilayers, where out-of-plane probes may be in 
different cell layers, thereby reporting the mechanical properties of another cell type. In order to 
reduce the impact of out of plane data, we employ a technique termed HiLo microscopy, which 
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can be used to optically section an image on a typical wide-field microscope. In brief, HiLo 
microscopy is a recently developed technique based on a structured illumination microscopy 
(SIM), and requires only a uniformly illuminated image and an image where a structured pattern 
is placed in the path of the light source89. In this technique, the high-frequency in-plane 
components of the image are extracted from the uniform image, while the low frequency 
components are extracted from the non-uniform (structured) image. To extract in-plane low 
frequency data, the local image contrast is multiplied by the uniform image to get a low 
frequency optically sectioned image. This in-plane low frequency image is then combined with 
the in-plane high frequency image to obtain the full-resolution optically-sectioned image. 
We were then able to employ this technique to eliminate almost all probe data 0.5 um or 
further from the image plane, and found (initially with a relatively simpler 3T3 cell bilayer) that 
out of plane probe removal significantly improved the accuracy of our PTM data. Finally, we 
used the HiLo based optical sectioning technique to measure the mechanical properties in both 
layers of control and diabetic myocyte-fibroblast bilayers to determine whether this more 
physiologic culture scenario reveals changes that were not apparent in the monolayers. 
2.2 Methods 
2.2.1 Cardiac cell isolation  
Cardiac fibroblasts (CFs) and myocytes (CMs) were isolated from 1-day old Wistar rat 
pups (Charles River, Wilmington, MA). Briefly, hearts were removed and placed in a dish 
containing Hank’s Buffered Salt Solution (HBSS, Cellgro, Manassas, VA) supplemented with 10 
units / mL penicillin and 10 ug/mL streptomycin. The hearts were then finely minced into 
another dish of HBSS with Pen-Strep. The heart pieces were then digested through a series of 
four digestions with trypsin (0.14%) and pancreatin (0.22mg/mL, Sigma) in HBSS. Following 
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the digestions, the cell solution was plated in a cell-culture treated flask, followed by an 
incubation at 37C at 1% CO2 for three hours. The CFs remained adhered to the flask while the 
CMs were removed with the supernatant. The supernatant was then passed through a 30um filter 
to remove large debris and the CMs were plated as described below. All animal protocols were 
approved by the Institutional Animal Care and Use Committee at Columbia University. 
2.2.2 Cell culture 
The CMs were plated with M199 containing 10% neonatal calf serum (NCS), Penicillin 
Streptomyocin (PS), 0.1mM 5-bromo-2-deoxyuridine (BrdU), and 0.2mM epinephrine (CM 
plating media) and were incubated at 37C and 1% CO2. For all high glucose experiments, except 
where specified, the day following the isolation, the media was again replaced with M199 
contained 5% NCS, PS, and BrdU, with either 5.5mM (low glucose – LG) or 30.5mM D-
Glucose (high glucose – HG). The myocytes were then cultured for two days before taking data. 
The 0.5mM palmitic acid (PA) and BSA-only media was made according to a previously 
established protocol 90. In brief, palmitic acid was dissolved in ethanol to a concentration of 
195mM, before being diluted in low-glucose M199 to its final concentration (in this case, 
0.5mM). As a vehicle for the palmitic acid, fatty-acid free BSA was also added to the media at a 
one-sixth molar ratio of the PA 90. The media containing palmitic acid was then placed in a 
shaking water bath at 37C until the media becomes limpid. The media was then supplemented 
with 20% NCS, PS, and BrdU. Unless otherwise stated, cells used in the high fatty acid 
experiments were treated with either 0.5mM PA or BSA only control media for 24 hours prior to 
taking data.  
 The remaining fibroblasts were fed with DMEM containing 10% FCS and PS, and were 
incubated at 37C and 5% CO2. When the CFs were ~90% confluent, the CFs are treated with 
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serum-free media for 2 hours to render them quiescent (to ensure that all CFs were treated with 
high glucose / PA for equivalent time). Except where noted, the CFs were then treated with 
either high glucose or high fatty acid media (same as CM media except with DMEM in place of 
M199 and with no serum) for 48 and 24 hours, respectively, prior to experiments. 
NIH 3T3 cells were cultured with DMEM (Sigma, St Louis, MO), 10% Fetal Bovine 
Serum (Aleken, Nash, TX), and PS at 5% CO2. 
2.2.3 Atomic force microscopy 
Atomic force microscopy (AFM) was used to compare the stiffness of cardiac myocytes 
plated on collagen-coated glass coverslips. In order to arrest contraction, myocytes were treated 
with 100mM KCl in Hank’s Buffered Salt Solution (HBSS, without calcium and magnesium) for 
one hour prior to cell indentation. An atomic force microscope (Bruker, Santa Barbara, CA) 
mounted on an inverted light microscope (Olympus IX81, Center Valley, PA) was used to 
measure the elastic moduli of the cells. The cantilever probe used was a silicon-nitride DNP 
probe (Bruker) with a pyramid shaped tip and a nominal spring constant of 0.12N/m. Each cell 
was indented at 1Hz in five different locations to find the average Young’s modulus for the cell.  
The deflection versus displacement data was then fit to an 8th order polynomial 91. The 
contact point was then identified as the first point at which the first and second derivatives were 
greater than an empirically determined threshold 91. The force was calculated as the product of 
the cantilever spring constant and the cantilever deflection. The following equation was then 
used to calculate the point-wise elastic modulus 92: 
E = F (1−ν
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For this formulation, D is the indentation depth, 2φ is the tip angle, b is the radius at which the 
tapered sides transition into a spherical tip R (set equal to b=Rcosφ), and m = 21/2/π for a 
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where n = 23/2/π for a pyramid-shaped probe. Elastic modulus values were statistically compared 
using a student’s t-test. 
2.2.4 Particle tracking microrheology experimental setup for monolayer 
 For cardiac myocyte and cardiac fibroblast monolayers, dishes were seeded with 1um 
fluorescent probes (Invitrogen) 24 hours before taking data. In order to arrest contraction, 
myocytes were treated with 100mM KCl in Hank’s Buffered Salt Solution (HBSS, without 
calcium and magnesium) for one hour prior to imaging cells. Both cardiac myocytes and 
fibroblasts were kept at 37C during imaging. Probes were imaged for approximately one minute 
at 16Hz using a 100x (1.3 NA) objective.  
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2.2.5 Particle tracking microrheology analysis for monolayer  
 Probes were tracked using a custom multiple particle tracking MATLAB (The Mathworks, 
Natick, MA) program. The change in position of particles was tracked over all frames, correcting 
for whole-field shifting (motion of the stage or dish). By averaging over the squared 
displacements of all particles at various time lags, the mean squared displacement (MSD) was 
obtained: 
Δr2 τ( ) = r t +τ( )− r t( )( )
2
t                   (5)
 
where r(t) describes the particle’s two-dimensional trajectory, and τ corresponds to time lag. The 
average MSD was then used to calculate the frequency-dependent storage (G’) and loss (G’’) 
moduli using an algebraic form of the generalized Stokes-Einstein relation (GSER) 93: 
                                
                (6) 
where 
 
         
                     (7) 
where kB is the Boltzman’s constant, a is the radius of the probe,  T is temperature of the probe 
environment (in Kelvin), and  
Γ 1+α"# $% ≈ 0.457(1+α)
2 −1.36(1+α)+1.90 .              (8)  
Extracted values of MSD (including the standard error) were compared at three different 
time lags (0.2s, 1s, 5s), which were chosen to represent the data across over two orders of 
magnitude. The positive and negative error for G’ and G’’ was calculated by determining G’ and 
G’’ for the MSD plus and minus the MSD standard error, respectively. G’ and G’’ were 
G '(ω) = G*(ω) cos(πα(ω) / 2)
G ''(ω) = G*(ω) sin(πα(ω) / 2),
α (ω ) ≡
∂ ln Δr2 (τ )
∂ lnτ
τ=1/ω
G*(ω ) ≈ 2kBT




presented as the value calculated from the average MSD with a range (G’low, G’high) and (G’’low, 
G’’high) corresponding to the values calculated from the MSD plus and minus the standard error. 
MSD values at the bottom and top layer at specified time lags were compared using a student’s t-
test. Statistical testing was not performed on G’ and G’’, as these are parameters derived from 
the MSD. 
2.2.6 HiLo optical setup and image processing 
We first acquired structured illumination data on fluorescent beads. The standard ‘wide-
field’ fluorescence image is called the uniform image. For non-uniform (structured) images, a 
Ronchi ruling (20 lines / mm, Edmund Optics, Barrington, NJ) was placed at the field stop 
between the mercury light source and the objective (60x, NA 1.3) of an Olympus IX81 inverted 
microscope. The grid was projected onto the focal plane of the sample during structured image 
acquisition. The Ronchi ruling was then removed to acquire a sequence of uniform images for 
PTM. All images were recorded with an ORCA R2 CCD camera (Hamamatsu, Bridgewater, NJ). 
The non-uniform image and the first frame of the uniform image sequence are then processed 
using the HiLo algorithm. 
The details of the HiLo analysis algorithm have been described in detail elsewhere 89, 94, 95. 
Briefly, the non-uniform In (

ρ)  and uniform images Iu (

ρ)  are the two raw images needed for 
acquiring the HiLo image, where ρ = x, y{ }  are the spatial coordinates in the image plane. These 
two images were used to define a partially demodulated image: 
Id












ρ( )  was then high-pass filtered to ensure the term was locally centered about zero 
prior to talking the absolute value. A low-resolution image was then obtained by applying a low-
pass filter to the partially demodulated image: 
Ilp

ρ( ) = LP Id

ρ( )!" #$.                                        (10) 
The cutoff frequency used for the low-pass filter is half of the spatial frequency of the grid 
pattern projected on the structured image. High-resolution information is obtained by applying a 
high-pass filter to the uniform image: 
Ihp

ρ( ) = HP Iu

ρ( )!" #$=1− LP Iu

ρ( )!" #$                (11)  







ρ( )                   (12) 
where η is an custom scaling factor, empirically adjusted until there is a seamless transition from 
high to low frequencies.  
2.2.7 HiLo-based image thresholding 
In order to generate depth resolved images for PTM, we used thresholding to objectively 
determine which probes were more than 0.5um from the focal plane. We calculated the 
percentage drop between the average intensity of each probe between the HiLo image and the 
first uniform image. Performing this calculation on the first frame is sufficient for determining 
which probes are out-of-plane in bilayer experiments, as the average probe displacement over the 
recorded time renders it unlikely that many probes would move out of frame or into frame during 
this time. Probes that experienced an average intensity drop greater than an empirically-
determined threshold were removed from the MSD calculation.  
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To determine this threshold, a z-stack was taken of a polyacrylamide (PAA) gel sparsely 
seeded with 200nm fluorescent probes (Invitrogen), with 100 images taken at intervals of 0.1um. 
A structured image was acquired approximately 10 frames the center of the stack (as beads over 
3um above the frame can not be seen clearly at the image plane), where there were multiple in-
plane and out-of-plane beads at various depths throughout the PAA gel. Because of the clarity of 
the gel, it was possible to determine the z-location of the embedded beads based on visual 
assessment of the bead sharpness. The uniform and HiLo-processed images were then compared 
to determine the drop in bead intensity as a function of the distance from the image plane using: 
 	  
%Drop = 100
( Iu -­‐ Ihilo )
Ihilo                         (13) 
These data were then used to establish a threshold for which most probes greater than 0.5 um 
from the focal plane were removed. 
2.2.8 Particle tracking microrheology experimental setup for bilayers 
 For particle tracking bilayer experiments, confluent NIH 3T3 cells plated on a collagen-
coated glass-bottomed cell culture dish (MatTek, Ashland, MA) were seeded with 400nm 
fluorescent beads as our PTM probes (Bangslabs, Fishers, IN) and allowed to incubate overnight. 
After 18 hours, another batch of 3T3 cells, which were also seeded with fluorescent probes, are 
plated on top of the confluent cell layer. The dish was then allowed to incubate for another 18 
hours before imaging.    
For the cardiac cell bilayers, fibroblasts were plated on top of myocytes, as myocytes on 
top of fibroblasts produced an unstable sheet. CMs were plated on collagen-coated coverslips. 
After the first day, the CMs were seeded with 1um fluorescent beads, and allowed to incubate 
overnight. One the second day, CFs were plated on top of the CM monolayer, along with 
 
 21 
additional fluorescent beads. In order to arrest contraction, bilayers were treated with 100mM 
KCl in Hank’s Buffered Salt Solution (HBSS, without calcium and magnesium) for one hour 
prior to imaging cells.   
 For high glucose experiments, both CMs and CFs were fed low or high glucose media on 
the first day following isolation (CFs in separate flask), so that the bilayer was treated from two 
days with the appropriate media. For high fatty acid experiments, high PA or BSA-only media 
was added at same time as CF plating.  
2.2.9 Particle tracking microrheology imaging and analysis for bilayer 
 Particle tracking data was acquired from the top and bottom layers of cell bilayers. 
Structured images were taken of each layer, followed by acquisition of a uniform (non-
structured) image sequence of the probes’ displacements over time. Image sequences (for each of 
the top and bottom layers), were imaged using a 60× (NA 1.42) oil immersion objective at 16 
frames per second for 1000 frames. In all cases, cells were maintained at 37C during imaging 
using a stage-top heater. 
We used a publicly available particle tracking code adapted from code by Crocker and 
Grier96 to select suitable probes (primarily based on bead intensity, radius, and eccentricity) on 
uniform images (termed Uniform data). Suitable probes were than tracked using a custom 
multiple particle tracking MATLAB (The Mathworks, Natick, MA) program. The trajectories of 
all probes, which experience an average drop in intensity greater than the empirically determined 
threshold, were removed from the data prior to the calculation of the MSD (termed HiLo data). 
The change in position of particles was tracked over all frames, correcting for whole-field 
shifting. The MSD, as well as the storage (G’) and loss (G”) moduli, was calculated according to 
Jonas et al. (2008) 67.  
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For the 3T3 cell bilayer experiment, statistical comparison were performed using a 
student’s t-test to compare MSD values at various time lags between the top and bottom layer for 
both Uniform and HiLo processed data. For the cardiac bilayer experiments, statistical 
comparison were performed using a student’s t-test to compare MSD values at various time lags 
between high glucose and low glucose and PA treated and BSA control for HiLo processed data. 
2.2.10 General approach summary to PTM in cell bilayer 
The experimental imaging and analysis protocol for the cell bilayer microrheology experiment 
was: 
1. Located area of cell bilayer suitable for microrheology (has beads). 
2. Adjusted focal plane until bottom cell layer was in plane. 
3. Placed Ronchi ruling at field stop and took one structured image of bottom layer. 
4. Removed Ronchi ruling and took sequence of uniform images. 
5. Adjusted focal plane until top cell layer was in-plane. 
6. Repeated steps 3 and 4 at top layer. 
7. Used MatLab program to determine beads that were suitable for tracking (based mainly 
on radius, brightness, and eccentricity). 
8. Processed the first frame of the uniform image sequences against the corresponding 
structured image for each layer using HiLo processing. 
9. Tracked all appropriate beads (e.g., beads that are too close together are excluded). 
Results from tracking all beads were denoted “Uniform”. 
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10. Using thresholds, removed trajectories of beads that were more than 0.5 um out-of-plane, 
based on the intensity reduction from the uniform to the HiLo frame. Results taken from 
images with out-of-plane probes removed were denoted “HiLo”. 
11. Extracted G’ and G” from the MSD. 
These results, denoted “HiLo” were compared to similar results without removal of out-of-plane 
beads, using only the uniform image sequence to track all trackable beads, denoted “Uniform.” 
Thus the Uniform results contain beads that were out-of-plane but still considered trackable. 
2.3 Results 
2.3.1 Atomic force microscopy on a diabetic cardiac myocyte monolayer  
Initially, AFM was used to assess the stiffness of cardiac myocytes treated with high 
glucose or high fatty-acid media, as compared to controls. Cardiac fibroblasts were not initially 
considered as myocytes make up the majority (approximately 75%) of the volume of the 
myocardium 97. Cardiac myocytes treated with 30mM glucose (n=18; 11.6 ± 1.2 kPa) for 48-
hours experienced a significant (p < 0.05) increase in stiffness compared to cells treated with 
5mM glucose (n=17; 7.5 ± 1.0 kPa) (Figure 2.1A). Cardiac myocytes treated with 0.5mM PA 
(n=20; 11.2 ± 1.0 kPa) also experienced a significant (p < 0.05) increase in stiffness compare to 
control myocytes (n=22; 8.7 ± 0.7 kPa) (Figure 2.1B).  
2.3.2 Particle tracking microrheology of a diabetic cardiac cell monolayer  
One limitation of AFM is that it requires direct contract with a cell to measure 
mechanical properties. However, to measure the mechanical properties of both layers of a 
cardiac cell bilayer requires a technique that does not require direct contact with the cell. We 
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therefore employed PTM to measure the viscoelastic properties of normal and diabetic cardiac 
bilayers. 
To determine whether PTM produces the same results as AFM, we initially used PTM to 
measure the passive frequency-dependent viscoelastic properties of cardiac myocyte and 
fibroblast monolayers treated with either a high glucose or a high fatty acid concentration. For 
the glucose data, we found that high glucose treated myocytes experienced a significant (p < 0.05 
for mid-range, p < 0.01 for high time-lags) reduction in MSD at mid-range and high time-lags 
with a subsequent increase in storage modulus over all frequencies. However, the loss modulus 
showed a mixed response, with high glucose producing an increase in loss modulus at lower 
frequencies, a decrease in loss modulus at higher frequencies, and little change at mid-range 
frequencies (Table 2.1, Figure 2.2). The PA treated cells experienced a significant reduction in 
MSD at low, mid-range and high time-lags (p < 0.001 for all) with a subsequent increase in both 
the storage and loss modulus across all frequencies (Table 2.1, Figure 2.3).  
These data indicate that high glucose and high fatty-acid conditions lead to significant 
changes in the viscoelastic properties of cardiac myocytes, suggesting that the increase in 
myocardial stiffness found in DC is at least partially due to an increase in myocyte stiffness. It 
should also be noted, that while both conditions produced an increase in cell stiffness, the 
increase in stiffness is more pronounced in the case of high PA treatment.  
We next aimed to measure the viscoelastic properties of cardiac myocyte/fibroblast 
bilayers to determine whether the more physiologic structural and biochemical interactions 
would have any impact on the results found for the diabetic bilayers. We first used PTM to 
measure the mechanical properties of monocultured CFs treated with high glucose or high fatty-
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acid to determine their baseline response to diabetic conditions. Unlike the myocytes, cardiac 
fibroblasts experienced no significant change in MSD with either treatment (Figure 2.4).  
In determining the mechanical properties of bilayers with PTM, it was necessary to 
consider the potential contribution of out-of-plane data to average mechanical properties. As 
PTM generally requires the tracking of bright fluorescent probes, all out-of-plane data can 
introduce significant errors in the measurement of mechanical properties. The accuracy of the 
measurement of the cell’s mechanical properties can therefore be improved by removing out-of-
plane data. Methods such as deconvolution or confocal imaging can address this issue, but are 
difficult, expensive, or are limited by the need for high-speed particle tracking. We therefore first 
developed a new technique, employing HiLo microscopy to reduce the contribution of out-of-
plane probes. 
2.3.3 HiLo-based threshold determination 
As fluorescent beads generally exhibit high fluorescence intensities, HiLo processing can 
not entirely quench the beads’ signals even if they are out-of-plane. However, as HiLo 
processing attenuates their intensities, with greater reduction of intensities occurring at greater 
distances out-of-plane, we were able to use HiLo processing to exclude out-of-plane beads. To 
do this, we determined a threshold for the reduction of intensity such that beads within ±0.5 um 
of the imaging plane are retained and so that beads out of this 1 um band could be excluded from 
analysis. 
To accomplish this, we compared the intensity of polyacrylamide gel-embedded 
fluorescent beads in uniform and HiLo-processed images at a range of distances from the focal 
plane (also called the imaging plane), which was approximately ten frames above the mid-plane 
of the image stack. The reduction in average bead intensities between uniform and HiLo images 
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increased with the beads’ distances from the focal plane (Fig. 2.5). We set a threshold at which 
we could remove a majority of beads 0.5um or further from the image while retaining a majority 
of beads 0.5um or closer to the image plane. Using data from the PAA gel z-stack, we 
determined the critical intensity reduction threshold was 20%. All beads 0.5um or closer to the 
focal plane had an intensity reduction less than 20%, while 88% of the beads greater than 0.5um 
from the focal plane had a reduction greater than 20%. Thus, by using this intensity reduction 
threshold, we were able to conserve all beads within the imaging plane and exclude all but about 
10% of the out-of plane beads. Additionally, due to the relationship between intensity drop and 
distance from the plane, it is likely that most of the included out-of-plane beads were close to the 
imaging plane. 
2.3.4 HiLo-based depth resolved microrheology of a cell bilayer 
In order to determine whether this method made a significant difference in PTM results, 
we used HiLo to remove out-of-plane probes from both the bottom and top layer of a living 3T3 
cell bilayer. 3T3 cells were used in the proof of concept experiment as they are an immortal cell 
lines and are simpler to culture and plate in bilayers than primary cardiac cells. The trajectories 
of the probes were used to calculate the average mean-squared displacement and then the storage 
and loss moduli of the cell layers over a continuous range of time lags (Fig. 2.6). Using the 
uniform image sequence (without out-of-plane bead removal), we showed that the MSD is 
elevated for the bottom layer of cells compared to the top layer except at low time lags. 
Comparisons of values at 0.2, 1 and 5 seconds (for MSD) or Hz (for G’ and G”) showed 
somewhat mixed results when the top layer is compared to the bottom layer.  The top cell layer 
exhibited significantly higher MSD than the bottom layer (p < 0.05) at 0.2s and 5s, and is 
comparable (non-significantly smaller) at 1s (Fig. 2.6(A,D)). Further, the storage modulus of the 
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top layer was slightly smaller than the bottom layer at 5 Hz and moderately larger at 1 Hz (Fig. 
2.6(B,E)). The loss modulus was mixed, with the top layer having a lower G” than the bottom 
layer at 1 Hz, but a higher value at 1 and 0.2 Hz (Fig. 2.6(C,F)). 
Next, HiLo processing was used to exclude beads greater than 0.5um from the focal plane. 
When we removed these probes’ trajectories from the MSD calculation, significant changes 
resulted. First, the top layer MSD became significantly lower than the bottom layer at 0.2s (p < 
0.05, Fig. 2.6D) and 1s (p < 0.01), and the p-value of the MSD comparison at 5s decreased (p < 
0.001). Second, both G’ and G” showed clear increases at all frequencies for the top layer 
compared to the bottom layer, and in almost all cases, the magnitude of the increase became 
much larger (Fig. 2.6(E,F)). For example, in the uniform data, the G’ of the top layer at 5 Hz was 
21% smaller than the bottom layer, whereas it was 119% higher for the HiLo data. These data 
demonstrated that depth-resolved microrheology yield much cleaner, more consistent results in 
heterogeneously plated samples. 
2.3.5 Causes of changes to MSD and complex moduli 
HiLo-based bead removal did not have a significant effect on the MSD (and subsequently, 
G’ and G”) when analyzing the probes from the bottom cell layer. The primary reason for this is 
that out of the bead trajectories removed from the bottom layer data (44 beads removed from a 
total of 185), it’s unlikely that many of the removed beads are from the top layer of cells due to 
the asymmetry in bead visibility (Fig. 2.5). The removal of out-of-plane beads produced a small 
reduction in MSD at short time lags (3% at 0.2s) and a small increase in MSD at mid-range (11% 
at 1s) and long time lags (15% at 5s).  
However, bead removal did have a significant effect on the MSD of the top layer (108 
beads removed from 268 total). This is because beads below the focal plane were more likely to 
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appear clearly in the top layer image (Fig. 2.5). Therefore, the trajectories of beads in the (softer) 
bottom layer were more likely to be included in the calculation of the top layer MSD. It follows 
that the removal of all out-of-plane bead trajectories from the top layer data had a significant 
impact on the average MSD, G’ and G” of the top layer (Fig. 2.6A). This effect was most clearly 
seen at low time lags (on a log-log plot), where there was a significant drop (64%) in MSD at 
τ=0.2s (Fig. 2.6D). Additionally, there was a clear change in slope of the top layer MSD at low 
time lags.  
Because the probes in the bottom layer cells exhibit a higher average MSD compared to 
the probes in the top layer cells, removal of the bottom layer probes from the top images should 
result in a decrease in MSD, which was observed (Fig. 2.6). However, there was also a change in 
slope at low time lags. The reason for the change in slope relates to the fact that bottom layer 
probes were out-of-plane in the top layer images. Because these probes were out-of-plane, they 
exhibited a smaller bead profile with lower, more uniform intensity magnitudes. Thus, the beads 
exhibited apparently increased MSDs at all time lags due to the overrepresentation of signal 
fluctuations. This apparent increase to the MSD made a larger difference at smaller time lags, as 
the storage and loss modulus were dependent on the slope of the MSD on a log-log scale (Fig. 
2.7).   
2.3.6 Confirmation of cell layer stiffness comparison 
Other groups have shown that many cell types can exhibit elastic moduli equal to, or 
lower than, the moduli of the underlying substrates 98, 99. On the other hand, certain cells are 
stiffer when plated on a confluent cell layer due to an increase in cortical stress fiber density 100. 
As it is not clear whether the HiLo results indicated the correct behavior (top layer being stiffer 
and more viscous), we validated the microrheological results using AFM. We confirmed that the 
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upper layer of a 3T3 cell bilayer exhibits a significantly higher elastic modulus than 3T3 cells 
plated on glass (p < 0.05; Fig. 2.8). One possible interpretation is that the top layer of cells 
becomes stiffer in order to protect the bottom layer from normal and shear forces. It is also 
possible that the top layer cell must create excess extra-cellular matrix components in order to 
adhere and spread onto the cell surface, as cell-cell forces have generally been found to be 
weaker than cell-matrix adhesion forces 101, 102. It is not currently known whether 3T3 cells will 
become stiffer on all softer substrates, as these experiments have not been systematically 
performed. 
Since conventional AFM requires direct contact with a cell to measure its mechanical 
properties, we are unable to measure the bottom layer of the cell bilayer. However, it is possible 
that the presence of the top layer of cells also changes the properties of the bottom layer cells. To 
address this, we compared the mechanical properties of the bottom layer of a bilayer with the 
properties of a monolayer plated on glass using conventional PTM (i.e., without HiLo 
processing). We found that cells in the monolayer exhibited similar MSD to cells in the bottom 
layer of a cell bilayer, indicating that the addition of cells to the top of a monolayer did not 
substantially alter the monolayer’s properties (Fig. 2.9).  
Our results thus indicated that the correction of out-of-plane beads using HiLo-based 
thresholding and processing was both accurate and vital for more precise characterization of cell 
properties. 
2.3.7 Measurement of viscoelastic properties of a myocyte / fibroblast bilayer 
 Once we determined that the HiLo-based bead removal method improves PTM data in 
bilayers, the technique was used to measure the viscoelastic properties of normal and diabetic 
cardiac bilayers consisting of cardiac fibroblasts plated on top of cardiac myocytes. At the 
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bottom layer (consisting primarily of CMs), high glucose treatment induced a significant 
decrease in MSD over the entire range of time lags (Fig 2.10(A,D)). This produced an increase in 
storage modulus (Fig 2.10(B,E)), though a somewhat mixed response from the loss modulus (Fig 
2.10(C,F)). This is consistent with what was measured in the CM-only monolayer, with high 
glucose treatment producing an increase in MSD over all time lags. At the top layer (consisting 
primarily of CFs), high glucose treatment produced no significant change in MSD (Fig 
2.10(A,D)), with a slight decrease in storage modulus at 1 Hz (Fig 2.10(B,E)), and a mixed 
response for loss modulus (Fig 2.10(C,F)). Again, this is consistent to what was found for the CF 
only data, where diabetic conditions produced no significant alteration in mechanical properties. 
 Similar to what we found for the CM monolayers, PA treatment produced a clear change 
in viscoelastic properties relative to the BSA-only control. At the bottom layer (consisting 
primarily of CMs), high PA treatment induced a significant decrease in MSD over the entire 
range of time lags (Fig 2.11(A,D)). This produced an increase in storage modulus (Fig 
2.11(B,E)) and loss modulus (Fig 2.11(C,F)) over the entire frequency range. At the top layer 
(consisting primarily of CFs), high PA treatment produced no significant change in MSD (Fig 
2.11(A,D)), with a slight decrease in storage modulus at 1 Hz (Fig 2.11(B,E)), and a mixed 
response for loss modulus (Fig 2.11(C,F)). Overall, these data confirm the results from the 
monolayer experiment, that high glucose and high fatty acid treatment increased cardiac myocyte 
stiffness, without affecting the stiffness of fibroblasts.  
2.4 Discussion 
 Treatment of cardiac myocytes with high glucose and high fatty-acid media both lead to 
an increase in passive and active stiffness, as measured by PTM and AFM, respectively. This 
data is consistent with in vivo experiments showing an increase in myocardial stiffness early in 
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the pathogenesis of DC 103. While this increase in myocardial stiffness is likely contributed to by 
increased collagen production of the fibroblasts 104, along with the fibrotic replacement of 
apoptotic/necrotic cells 105, the results presented here suggest that at least some of the increased 
stiffness in diabetic hearts is due to an increase in the stiffness of cardiac myocytes. Additionally, 
while van Heerebeek et al (2008) previously showed that increased myocyte stiffness can occur 
in late stage diabetic heart failure 106, this is the first DC study that indicates that increased 
myocyte stiffness may be induced by diabetic conditions at an early age. 
The benefit of using PTM to measure cell mechanical properties is that the technique 
yields local frequency dependent viscoelastic properties. While other techniques (AFM, 
magnetic micromanipulation, optical trap) can measure the viscoelastic properties of cells, these 
techniques generally require direct contact with the cell, and require the use of specialty 
equipment to obtain data. In this study, we find that high glucose treatment has a significant 
effect on myocytes at low and mid-range time lags, but a smaller difference at higher time lags. 
As lower time lags are associated with the solid components of the cell (due to effects of short 
term cytoskeletal fluctuations), and higher time lags are associated with fluid components of the 
cell (due to the probe being able to diffuse though the cytoskeleton), this suggests that high 
glucose conditions has a greater effect on the solid components of the cells 107. For example, a 
time lag of 0.2s (frequency of 5Hz) represents the approximate heart rate of a 1-day old neonatal 
rat 108. This is consistent with the storage and loss moduli derived from the MSD, where high 
glucose treated myocytes have a larger storage modulus across over all frequencies, but a much 
more variable loss modulus across frequencies (higher at low frequencies and lower at high 
frequencies). For high fatty-acid treated cells, this decrease in MSD is significant across all time 
lags, with a subsequent increase in both storage and loss moduli over all frequencies. 
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One difficulty in measuring the mechanical properties of cardiac myocytes with PTM is 
the active contraction of the cells. PTM yields the storage and loss moduli of cells from the 
passive particle motion of probes embedded in the cells. Any active motion of the cell can 
severely limit the accuracy of the data because the passive motion of the beads is combined with 
active motion of the cell or cellular components 107. By treating the myocytes with potassium 
chloride, we were able to halt beating, without significantly altering cell morphology.  
Another major benefit of using PTM is the technique’s ability to measure the mechanical 
properties of cells without directly contacting the cell. This provides a major advantage in 
studying the properties of cells in three-dimension culture scenarios such as co-cultured bilayers 
and embedded in constructs. While we did not measure any changes in the mechanical properties 
of cardiac fibroblasts plated in monolayers, we believed that the presence of fibroblasts, as well 
as the more physiologic bilayer construct could have revealed behavior that was not apparent in 
the comparably simple monolayers. Additionally, it was also possible that the presence of 
fibroblasts could reduce or possibly exacerbate the increase in stiffness found in high glucose 
and high fatty acid treated myocytes. Overall, this step was necessary to better extend our results 
to the myocardium. 
We therefore used the HiLo-based method established in this chapter to measure the 
mechanical properties of normal and diabetic bilayers (high glucose and high fatty acid 
treatment) consisting of cardiac fibroblasts plated on top of cardiac myocytes. These data 
indicated that high glucose and high fatty-acid treatment produces an increase in the stiffness of 
cardiac myocytes with no significant change in the stiffness of the top layer of fibroblasts. One 
difference found in the bilayer data compared to the monolayer data is that the high glucose 
treated myocytes have a significantly lower MSD than the low glucose treated myocytes over the 
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entire range of time lags (whereas the difference at low time lags for high glucose treated 
monolayer was not significant). However, the comparative loss moduli for the low glucose and 
high glucose treated CMs are still variable across the frequency range. Overall, these data 
suggest that the increased myocardial stiffness found in the earlier stages of DC is at least 
partially due to an increase in cardiac myocyte stiffness, though not in fibroblasts. However, the 
presence of fibroblasts in the bilayer plating revealed behavior that was not apparent in the 
comparably simple monolayers, such as the increased MSD in both cell types when plated 
together, and the changes to CM properties at low time lags.  Thus, CFs may play an indirect 
regulatory role in establishing the stiffness of cardiac cells, in addition to their role in regulating 
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Table 2.1: G’ (Pa) and G’’ (Pa) for CM monolayers treated with low glucose (LG), high glucose 
(HG), BSA and palmitic acid (PA) at various frequencies. No data (ND) is reported when the 
value of G’ or G’’ is negligible at a given frequency. The numbers are displayed as the complex 
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Table 2.2: G’ (Pa) and G’’ (Pa) for CM / CF bilayers treated with LG, HG, BSA and PA at 
various frequencies. No data (ND) is reported when the value of G’ or G’’ is below zero at a 
given frequency. The numbers are displayed as the complex moduli components, with the range 













Figure 2.1: AFM measurements on cardiac myocytes treated with high glucose compared to low 
glucose control (A) and with 0.5mM palmitic acid (PA) compared to BSA only control (B). Both 
the high glucose and high PA treated experience a significant increase in elastic modulus 
compared to the controls (p < 0.05). 
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Figure 2.2: Line and bar plots of MSD (nm2) vs. tau (s) (A,D), G’ (Pa) vs. frequency (Hz) (B,E), 
and G’’ (Pa) vs. frequency (Hz) (C,F) of cardiac myocytes treated with low glucose (5mM) and 
high glucose (30mM) media for 48 hours. High glucose treated myocytes have a significantly 
lower MSD at mid-range and high time lags, with a higher storage modulus over the entire 
frequency range. Loss modulus data is mixed, with high glucose treated CMs having a larger 




        
Figure 2.3: Line and bar plots of MSD (nm2) vs. tau (s) (A,D), G’ (Pa) vs. frequency (Hz) (B,E), 
and G’’ (Pa) vs. frequency (Hz) (C,F) of cardiac myocytes treated with BSA-only vehicle control 
media (BSA) and 0.5mM PA (PA) media for 24 hours. High glucose treated myocytes have a 
significantly lower MSD over the entire range of time lags, with higher storage and loss moduli 
over the entire frequency range. Loss modulus data is mixed, with high glucose treated CMs 
having a larger modulus below 1Hz but a lower modulus above 1Hz. (*p < 0.001) 
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Figure 2.4: MR measurement of cardiac fibroblasts treated with high glucose compared to low 
glucose (A) and with 0.5mM palmitic acid compared to BSA only control (B). Fibroblasts show 













Fig. 2.5: The percentage drop in bead intensity between uniform and HiLo images (relative to 
HiLo) at increasing distances from the focal plane. Beads 0.5um or closer to the image plane 
have a drop in intensity less than 20%, and 88% of beads 0.5um or further from the image plane 
had a drop in intensity greater than 20%. The asymmetry in the bead distribution results from the 
inverted configuration of the microscope; objects below the imaging plane could be observed to 




Fig. 2.6: Plot of MSD (nm2) vs. tau (s) (A), G’ (Pa) vs. frequency (Hz) (B), and G”(Pa) vs. 
frequency (Hz) (C) for bottom and top cell layers with and without HiLo image processing. HiLo 
processing allows for the removal of out-of-plane beads. Removing the out-of-plane beads from 
each image produces a small increase in the MSD of the bottom layer and a larger decrease in the 
MSD of the top layer over all time lags. These alterations in MSD produce a decrease in the 
storage and loss modulus in bottom layer and an increase of the storage and loss modulus in the 
top layer. The MSD (D, in nm2), storage modulus (E, in Pa), and loss modulus (F, in Pa) are 
compared at three different time lags. All data are compared using a student’s t-test (*p < 0.05, 
**p < 0.01, ^p < 0.001). Statistical analysis at not performed for G’ and G’’, as these are derived 
parameters. G’ drops to zero above 0.2Hz, so was not included in the plot (E). 
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Fig. 2.7: Comparison of the appearance (A,B), trajectory (C,D), and MSD (E) of a single bead as 
seen at the bottom layer (in-plane) and the top layer (out-of-plane). The out-of-plane bead (B) 
appears smaller than the in-plane bead (A) with a more uniform intensity distribution. This 
increases the contribution of signal fluctuations and decreases the centroid-finding resolution of 
the tracking program. Because of this, short time-lag displacements of the out-of-plane bead (D) 
are much larger than the displacements of the in-plane bead (C) on the log-log scale. The result is 
that analysis yields an increase in MSD magnitude and decrease in slope (E), the effect of which 





Fig. 2.8: AFM testing shows that 3T3 cells plated on a 3T3 monolayer have a significantly 
higher elastic modulus (kPa) than 3T3 cells plated on glass (n=11 for both cases; *p < 0.05 as 










Fig. 2.9: MSD (nm2) vs. Tau (s) plot comparing properties of 3T3 cell monolayer with the top 
and bottom layers of a 3T3 cell bilayer.  The monolayer is shown here as having properties 
similar to the bottom layer of the bilayer, showing that the presence of the top layer of cells does 

















Figure 2.10: Plot of MSD (nm2) vs. tau (s) (A), G’ (Pa) vs. frequency (Hz) (B), and G”(Pa) vs. 
frequency (Hz) (C) for bottom (B) and top (T) myocyte/fibroblast layers with low glucose (LG) 
and high glucose (HG) media. At the bottom layer (consisting primarily of CMs), high glucose 
treatment induces a significant increase in MSD over the entire range of time lags (D). This 
produces an increase in storage modulus, though a somewhat mixed response from the loss 
modulus. At the top layer (consisting primarily of CFs), high glucose treatment produces no 
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significant change in MSD, with a slight decrease in storage modulus at 1 Hz, and a mixed 
response for loss modulus. Data are compared using a student’s t-test (*p < 0.05, **p < 0.01, ^p 
< 0.001). Statistical analysis at not performed for G’ and G’’, as these are derived parameters. G’ 










Figure 2.11: Plot of MSD (nm2) vs. tau (s) (A), G’ (Pa) vs. frequency (Hz) (B), and G”(Pa) vs. 
frequency (Hz) (C) for bottom (B) and top (T) myocyte/fibroblast layers with and BSA control 
(BSA) and 0.5mM PA (PA) media. At the bottom layer (consisting primarily of CMs), high PA 
treatment induces a significant increase in MSD over the entire range of time lags (D). This 
produces an increase in storage modulus and loss modulus over the entire frequency range. At 
the top layer (consisting primarily of CFs), high PA treatment produces no significant change in 
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MSD, with a slight decrease in storage modulus at 1 Hz, and a mixed response for loss modulus. 
Data are compared using a student’s t-test (*p < 0.05, **p < 0.01, ^p < 0.001). Statistical 
analysis at not performed for G’ and G’’, as these are derived parameters. G’ drops to zero above 




















Chapter 3. Assessing Functional Changes in Cardiac Myocytes Due to Diabetic Conditions 
3.1 Introduction 
 In the pathogenesis of DC, diabetic conditions produce alterations on the cell level, which 
lead to functional changes in cardiac performance 52, 103. Currently, most in vitro DC work 
focuses on pathway level studies, which can show, for example, how hyperglycemia leads to 
calcium mishandling, but can not necessarily relate what form this impaired contraction takes 
(such as reduced contractile force, diastolic dysfunction, systolic dysfunction, or some 
combination). On the other hand, in vivo studies can measure whole heart functional properties 
with and without various treatments, but can not determine the precise mechanism by which any 
benefits are produced. This limits the ability of researchers to understand the mechanism by 
which diabetic conditions produce dysfunction, which in turn limits our ability to develop 
treatments for DC. By creating an in vitro model of cardiac contraction, it would be possible to 
link specific diabetic conditions with dysfunction, as well as assess various treatments and 
potential therapeutic targets.  
 The in vitro model we chose employs micropillars to measure the contractile properties 
of cardiac myocytes. Micropillars were originally created to measure the traction force of cells, 
and have recently been used to explore the force-generating properties of myocytes 79, 109. One 
benefit of using micropillars to measure contractile properties is that it is possible to tune the 
effective modulus of the pillar array to a desired stiffness. This allows the surface of the 
micropillar array to mimic the stiffness of the myocardium. Additionally, the technique for 
measuring the contractile force throughout contraction and relaxation is relatively 
straightforward, as the force on each pillar is directly proportional to its displacement through a 
beam bending equations 79, 110. By analyzing the force trace throughout myocyte contraction and 
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relaxation, it is possible to measure contractile force, as well as assess for systolic and diastolic 
dysfunction. 
For this study, we first aimed to determine whether high glucose and fatty acid 
environments altered cardiac cell contractile properties (in terms of contractile force and 
dysfunction). Finding that these treatments increased the presence of diastolic dysfunction 
(without significantly altering systole or contractile force), we explored the role that oxidative 
stress has in producing cardiac dysfunction. The increase in ROS (through both intracellular and 
extracellular sources) contributes to dysfunction through direct damage to proteins and DNA 38. 
The protein TXNIP (thioredoxin interacting protein) has been shown to have a major role in 
regulating intracellular ROS in cardiac cells 45, 111, 112. TXNIP binds and inhibits the thioredoxin 
(TRX) protein group, which itself inhibits ROS production in cells. Hyperglycemia, by 
upregulating TXNIP expression, inhibits TXN, thereby inducing oxidative stress within the cell. 
The anti-oxidant N-acetylcysteine (NAC) has been shown to decrease thioredoxin interacting 
protein (TXNIP) expression in high-glucose treated rat mesangial cells 113. Additionally, NAC 
improves cardiac performance in diabetic rats (in terms of fibrosis and diastolic dysfunction) via 
reduction in reactive oxidative species (ROS), attenuation of myocyte hypertrophy, and 
reduction in total collagen production in the heart 114. By treating myocytes with NAC in our in 
vitro model in conjunction with other biological assays, we can better assess the role of oxidative 
stress in dysfunction, explore the mechanism by which NAC reduces dysfunction, as well as 
assess a potential therapeutic target (TXNIP) for DC. 
In addition to oxidative damage, systolic and diastolic dysfunction in DC are commonly 
associated with hypertrophy as well an increase in stiffness in the myocardium 115. As shown in 
Chapter 2, diabetic conditions produce an increase in cardiac myocyte stiffness. As NAC has 
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been shown to reduce cardiac dysfunction in vivo 47, it follows that NAC may contribute to 
reduced dysfunction by reducing myocyte stiffness or hypertrophy.  Additionally, hypertrophy is 
correlated with increased ROS production in cardiac cells 116, and has also been linked to 
increased myocyte stiffness in later stage of diabetic heart failure 106, 117. We therefore developed 
the relationship between hyperglycemia / hyperlipidemia and hypertrophy, as well as considered 
the contribution of increased ROS production on both hypertrophy and cardiac cell mechanical 
properties, through both directly adding ROS to cells and via treatment with NAC.  
3.2 Methods 
3.2.1 Cell culture 
Cardiac myocytes were isolated and cultured as described in Section 2.2. For specified 
cases, hydrogen peroxide (HP) was added to the media at specified concentrations, or N-Acetyl-
Cysteine (NAC) was added to media at a concentration of 1uM. 
3.2.2 Micropillars creation and preparation 
Silicone micropillars were used to measure the functional properties of cardiac myocytes 
under various treatment conditions. PDMS micropillars were prepared according to Ganz et al. 
(2006) and du Roure et al. (2005) 118, 119. First, silicon wafers (created by Dr. Lance Kam who 
kindly allowed us to use them) were patterned with an array of cylindrical pits using 
photolithography followed by a deep-etching process. The desired pattern was then replicated by 
positive photoresist by photolithography. The wafer was then etched down to the desired depth 
to obtain the negative pattern of the array. Each micropillar array is approximately 1cm by 1cm, 
with the pillar dimensions defined by Figure 3.1. 
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PDMS (Sylgard 184) was added to the glass portion of a 35mm glass-bottomed dish 
(MatTek), which was then placed in a vacuum chamber for approximately 15 minutes to remove 
air bubbles within the PDMS. The silicone template was then placed on top of the PDMS (pillar-
side down), which is then allowed to cure overnight (at 65C). The PDMS-coated wafer was then 
submerged in ethanol, where the wafer is removed from the silicone. The PDMS micropillars are 
then stored in sterile water until the day of the experiment. The effective modulus of the 
micropillars was determined by the elastic modulus of the PDMS (~2MPa as measured by 
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with EP being the elastic modulus of the PDMS and the other parameters defined by Figure 3.1. 
The pillar dimensions were then chosen to give an effective modulus that represented 
approximately what is found in myocardial tissue (~10 kPa) 76. 
The micropillars were coated with 20ug/ml FN for two hours at 37C. The CMs were 
isolated as specified above and plated sparsely (2.5e5 myocytes per 35mm dish) on the 
micropillars. CMs were treated with either high glucose for 48 hours, or high palmitic acid (PA) 
media for 24 hours. For the NAC experiments, 1uM NAC was added along with the media 
during treatment. For the hydrogen peroxide (HP) experiments, CMs were treated with HP in 
low glucose control media for 24 hours prior to imaging. 
3.2.3 Micropillar imaging and analysis 
The CMs were imaged on an inverted IX81 Olympus confocal microscope using a 40x 
1.4 NA oil objective. The cells were maintained at 37C during imaging. Once an individual CM 
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was located, we initiated a scan in the z-axis until the tops of the pillars were located. The tops of 
the pillars were then imaged at maximum frame rate (~15 Hz) during CM contraction. This 
video-rate acquisition provides information during spontaneous contraction of the myocytes. 
Once the images were recorded, the positions of the tops of the pillars were tracked using 
the Particle Tracker module in ImageJ. The following formula (based on the cantilever beam 
bending equation) was then used to calculate the force applied by the cell on a single pillar: 
 
                  (2) 
where δ is the x-y displacement of the top of the pillar. The final force calculation was also 
corrected for motion due to pillar shear and tilt 120. Active actin-myosin contraction force was 
calculated as the difference in forces between the minimum (relaxation) and maximum 
(contraction) pillar deflections.  
Additionally, the force trace of the active contraction was used to determine if there is 
any dysfunction during contraction and relaxation (Figure 3.2). For our purposes, the contractile 
phase (or systole) was defined as an increase in applied pillar force over noise levels (force levels 
during uncontracted state) (Figure 3.2(A)), while the relaxation phase (or diastole) was defined 
as the portion of the trace where the force returns from its peak to noise levels (Figure 3.2(A)). A 
systolic disruption was said to have occurred in the contractile case when a drop in force occurs 
prior to the cell reaching its peak-applied force. A diastolic disruption was said to have occurred 
if there is a sudden increase in applied force during the relaxation phase (during return from peak 
form to noise level – Figure 3.2(B)). Diastolic disruption was also said to have occurred when 
the myocyte remained in a fully contracted state for an extended time prior to relaxation. 
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3.2.4 ROS assay 
 Intracellular ROS generation was measured with 5-(and-6)-chloromethyl-2’,7’-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Invitrogen). CMs are plated 
in a 96-well plate. After two days, the cells are incubated with HBSS containing 10uM CM-
H2DCFDA at 37C for 30 minutes. After 30 minutes, the cells are washed with warm HBSS three 
times, and serum free media (with various treatments) is added to the wells. The average 
fluorescence (490nm excitation, 520nm emission) for each cell condition is measured with a 
microplate reader (BioTek). 
3.2.5 Immunoblotting 
Immunoblotting was performed on CMs lysed in standard RIPA lysis buffer containing 
500 nM phenylmethanesulfonyl fluoride, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 
10 mM sodium pyrophosphate, and protease inhibitor cocktail. Samples were solubilized in LDS 
sample buffer supplemented with 5% w/v 2-mercaptoethanol. Total protein concentration was 
determined by Bradford assay (Sigma). Soluble fractions containing equal amounts of total 
protein were separated using SDS polyacrylamide gel electrophoresis and transferred onto PVDF 
membranes (Millipore, MA). Immunoblotting was performed with goat anti-mouse antibodies 
for cFos (Abcam, 1:250), TXNIP (MBL International, 1:400) and horseradish peroxidase 
conjugated goat anti-mouse secondary antibody (Biorad, 1:1000). Blots were developed with 
ECL reagents (Perkin Elmer, MA) and imaged using a FUJI imaging unit (Fujifilm, CT). 
Relative band intensities in immunoblotting images were quantified using ImageJ, with values 





3.3.1 Diabetic cardiac myocyte contraction 
We first determined whether high glucose and high fatty-acid treatment alone would alter 
contractile force or induce diastolic or systolic dysfunction. We found that while neither 
treatment produced a change in contractile force (Figure 3.3), both lead to a significant increase 
in the percentage of cells that experience diastolic, though not systolic, dysfunction (Table 1). 
These results mirrored what is found in early-stage DC, where diastolic dysfunction occurs, 
though generally not systolic dysfunction. 
Oxidative damage through excessive ROS production is commonly linked with cardiac 
dysfunction. To explore the role that ROS has in dysfunction, CMs plated on micropillars were 
treated with low glucose media supplemented with 10uM HP for 24 hours. We demonstrated that 
10uM HP significantly increased occurrences of dysfunction over control, and that the addition 
of NAC significantly reduced the abnormalities to control levels (p < 0.05) (Table 1). No 
significant differences were found in systolic abnormalities. 
We next determined whether NAC reduced diastolic dysfunction in our in vitro DC 
model. Using contingency table analysis to compare treatment groups (LG/HG ± NAC and 
BSA/PA ± NAC), we found that NAC reduced the incidence of such dysfunction back to control 
levels in both the high glucose and high PA cases (p < 0.05) (Table 1). Additionally, we found 
that adding NAC to myocytes in control media produced no significant changes in diastolic 
dysfunction. We did not find any changes in cardiac myocyte contractile force in any of these 
cases (Figure 3.3). 
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3.3.2 ROS production in high glucose and fatty-acid treated cells 
 Since ROS apparently increases cardiac myocyte dysfunction, and treatment with the 
anti-oxidant NAC reduced dysfunction in our in vitro model, we next assessed whether glucose 
and fatty-acid treatment increased ROS levels in cardiac myocytes. ROS levels were measured 
with a fluorescent ROS indicator dye (CM-H2DCFDA). We measured no significant change in 
HG treated CM cells relative to LG treated cells (Figure 3.4(A)). However, both LG+NAC and 
HG+NAC treated cells experience a significant decrease in ROS levels relative to LG and HG, 
respectively.  
Palmitic acid treatment does produce an (non-significant) increase in ROS levels relative 
to the BSA control (Figure 3.4(B)). Unexpectedly, NAC treatment also seems to increase ROS 
levels in both the BSA control and PA treated CMs. These results may be due to cross-
interference from the compounds being used. Alternatively, ROS levels may in fact be elevated, 
suggesting that NAC’s protective role may not lie in directly harvesting ROS. In support of the 
former hypothesis, ROS levels for the BSA-only vehicle control are approximately 10-fold 
smaller than ROS levels for the LG control. It is unclear why this is the case, though it is 
possible that the presence of BSA in the media either attenuates ROS production or interferes 
with the fluorescence expressed by the ROS indicator.  
 In order to place the ROS results in proper context, we performed a ROS sensitivity assay 
on CMs treated with increasing concentrations of hydrogen peroxide (Figure 3.4C). We found 
that the CM-H2DFCDA assay only detected an increase in intracellular ROS levels at large 
concentrations of hydrogen peroxide (enough to reduce viability in cardiac myocytes). Indeed, 
while 10uM HP has been shown to increase the presence of diastolic dysfunction in cardiac 
myocytes (see previous section), the CM-H2DFCDA assay did not measure an increase in ROS 
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at this treatment level. This leaves open the possibility that high glucose treatment increases 
ROS-levels in cardiac myocytes enough to induce dysfunction but below the ROS detection 
threshold. 
3.3.3 No change in TXNIP levels in CMs with high glucose and NAC treatment  
 Our ROS assay supports the hypothesis that NAC reduces cardiac dysfunction in high 
glucose cases by reducing ROS levels in cardiac cells. To further develop the mechanism by 
which NAC reduces dysfunction, as well as investigate a potential therapeutic target for treating 
dysfunction, we explored a potential pathway by which NAC impacts ROS regulation in cardiac 
myocytes. To assess the regulation of ROS through the TXNIP pathway, we measured the 
protein levels of TXNIP in CMs with high glucose and NAC treatment. However, we found that 
high glucose treatment does not have a significant effect on TXNIP levels in CMs, suggesting 
that this pathway may also have a limited effect in DC (Figure 3.5). 
3.3.4 Hypertrophy in diabetic cardiac cells 
 Because we found that diabetic conditions increase dysfunction, we next aimed to 
determine whether these conditions would also induce hypertrophy, which is also linked to 
dysfunction in DC 121. We examined whether hypertrophy (cell size growth) is induced by high 
glucose or high fatty acid treatment, and whether NAC affects any such diabetic-induced 
hypertrophy. To achieve this, we immunoblotted for common hypertrophic indicator cFos, which 
is a key regulator of cardiac hypertrophy and may be implicated in DC progression 122, 123.  For 
the high-glucose case (and its control), the media was supplemented with 20% NCS (instead of 
5% NCS). At the regular serum concentrations, we were unable to obtain western blot bands at 
the correct molecular weight.  
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High glucose treatment produced a non-significant increase in cFos levels, although the 
variability of the response was high (Figure 3.6(A,B)). Additionally, the levels of cFos in 
response to NAC treatment (for both LG and HG cases) varied from litter to litter. Indeed, in 
some litters, NAC produced a decrease in cFos, while in other litters, NAC produced an increase 
in cFos. Interestingly, we did not find this response in the BSA-only control case, suggesting that 
the presence of BSA reduced the variability in CM response.  
CMs treated with palmitic acid experienced a significant increase in cFos levels (p < 
0.01) compared to the BSA-only control cases (Figure 3.6(C,D)). High fatty-acid treated CMs 
additionally treated with NAC exhibited a reduction in cFos levels to control levels, while 
control cells treated with NAC exhibited no change in cFos.  
 We additionally directly measured the response of CM hypertrophy to ROS, by treating 
CMs with hydrogen peroxide (HP) for 24 hrs. When we dosed with HP, only the highest 
concentration (50 uM) led to elevated cFos, and cells appeared unhealthy at that dose (p<0.05, 
Figure 3.6(E,F)). These results indicate that the signaling changes associated with diabetic 
conditions may be specific to fatty acid elevation and not to effects of glucose or ROS alone. 
Indeed, HG treated CMs experienced at most a below threshold increase in ROS production, as 
well as a small, non-significant increase in cFos. Conversely, while NAC treatment significantly 
reduced ROS levels in low and high glucose treated CMs, NAC did not have a significant effect 
on cFos in these cells. This suggests the possibilities that the hypertrophic response to NAC is 
more variable than the ROS response, or that NAC contributes to regulating hypertrophy through 
other mechanism in addition to ROS reduction. 
 
 59 
3.3.5 Relationship between ROS production and stiffness 
 We next used PTM to determine whether a direct addition of ROS (through hydrogen 
peroxide) would increase CM stiffness. We found that 24 hour treatment with 10uM hydrogen 
peroxide had no significant effect on CM viscoelastic properties in terms of MSD (Figure 3.7). 
These results indicated that direct addition of ROS (at least at moderate levels) does not directly 
produce an increase in stiffness. Higher concentrations of HP altered the morphology of the cell 
monolayer, so data from these cells were not considered. 
3.3.6 Impact of NAC treatment on cell mechanical properties 
 Although we did not find a direct relationship between ROS and increased cell stiffness, 
NAC treatment demonstrated the ability to modulate dysfunction (for both high glucose and PA 
treatment) and reduce hypertrophy (at least in PA treated CMs). As NAC has been shown to 
reduce dysfunction and hypertrophy in vitro and in vivo 47, and as hypertrophy can increase CM 
stiffness, we next aimed to determine whether NAC could modulate the increased stiffness found 
in diabetic CMs, even though NAC’s primary role is an antioxidant. We used PTM to measure 
the viscoelastic properties of CMs treated with normal and high glucose / fatty-acid media, with 
and without NAC. This assay was performed with cardiac myocytes only, as we determined in 
Chapter 2 that only myocytes increase in stiffness in diabetic conditions, with or without 
fibroblast co-culture. Additionally, cardiac fibroblasts make up a relatively small volume of the 
myocardium, so any change in mechanical properties would be unlikely to have an effect on 
overall myocardial stiffness. 
HG+NAC treated CMs experience a significant increase in MSD at both 1s and 5s (p < 
0.01) relative to HG, within the same level as the LG treated case (Figure 3.8). LG+NAC treated 
CMs experience no significant change in MSD compared to the LG only cases. As expected, the 
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increase in MSD for the HG+NAC cases relative the HG case, leads to a decrease in storage 
modulus across all frequencies (though still higher than the LG case). However, the response of 
the loss modulus to NAC treatment is variable. 
 Addition of NAC partially modulates the increase in stiffness found in PA treated CMs 
(Figure 3.9), with PA+NAC treated CMs experiencing a significant increase in MSD at 0.2s (p < 
0.05) with smaller non-significant increases at 1s and 5s. Interestingly, NAC-treatment also leads 
to a significant increase in BSA only-treated CMs at 5s (p < 0.01), suggesting that NAC may 
also impact the stiffness of non-diabetic cells. The increase in MSD for the PA+NAC cases 
relative to the PA case, leads to a decrease in storage modulus and loss modulus over all 
frequencies. The BSA+NAC treated CMs have a larger storage modulus than the BSA-only 
treated CMs at 1Hz, though a similar storage modulus at 5Hz. The comparative loss-moduli of 
the BSA+NAC and BSA-only cases are variable across the frequency range. Overall, these data 
indicate that NAC produces a moderate reduction in the increased stiffness found in cardiac cells 
as produced by high glucose and high fatty-acid conditions.  
 
3.4 Discussion 
 Currently, cell-level dysfunction is mainly associated with improper calcium handing and 
oxidative damage 103. For this study, we focused on the contribution of oxidative damage to 
dysfunction. By treating the CMs with an antioxidant, we aimed to reduce ROS, and thereby 
oxidative damage to the cells. We showed that NAC-treatment produced a significant reduction 
in the percentage of cardiac myocytes (exposed to high glucose or high-fatty acid environments), 




 To determine if NAC reduced cardiac dysfunction through reducing ROS, we measured 
ROS levels with HG or PA treatment, with and without NAC. The ROS assay did not show a 
clear change in ROS levels with HG. Indeed, current research shows a mixed response in ROS 
production for cardiac cells treated with high glucose. Indeed, while some studies report an 
increase in ROS levels with 24-hr glucose treatment 47, 124, other studies either show no 
significant response 125, or require additional supplements to generate a response 126. The 
variable results presented here along with the data from previous literature suggest an unclear 
relationship between glucose and ROS in cardiac cells. NAC treatment, however, did produce a 
significant drop in ROS levels in both LG and HG treated cells, as well as a significant reduction 
in diastolic dysfunction, suggesting a correlation between a reduction in ROS levels and a 
reduction in dysfunction in HG treated CMs. 
 The effect of PA treatment on CM ROS production is still indeterminate. To assess 
whether there was any cross-interference between the compounds, we used the ROS assay on the 
BSA and PA media (with and without NAC), but with no cells, and while we did measure a 
small increase in ROS levels in the PA and PA+NAC cases, this increase does not account for 
the large jump seen in CM ROS assay. We additionally performed this assay on the low and high 
glucose media (with and without NAC) and found no change in ROS levels. While there is 
currently no research directly relating ROS production in cardiac cells to treatment with high 
fatty acid, a study with endothelial and smooth muscle cells shows that treatment with palmitic 
acid produces a significant increase in ROS production 127.  
  In addition to determining whether NAC reduces dysfunction in our in vitro model, we 
wanted to examine the pathway by which NAC affects ROS regulation. In this study, we 
assessed the effect of high glucose and NAC on TXNIP expression in CMs, and found no 
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significant change in TXNIP levels in any case. This result indicated that the TXNIP / TXN 
pathway likely does not play a significant role in early stage DC. 
In terms of structural changes, we also investigated the role that diabetic conditions may 
play in myocyte hypertrophy, which plays an important role in cardiac dysfunction in vivo 103. 
Cardiac myocytes treated with PA experienced a significant increase in cFos (a common 
hypertrophic marker) levels, with NAC treatment reducing cFos to control levels. CMs treated 
with HG experience a non-significant increase in cFos, while addition of NAC to the HG media 
produces a small non-significant decrease in cFos levels. Interestingly, CMs treated with low 
glucose media supplemented with NAC, varied significantly in terms their cFos levels, with 
some isolations expressing reduced cFos, while other showing a 2-fold increase in cFos. These 
data suggested that cardiac cells can experience a variable hypertrophic response when treated 
with NAC.  
We also found that NAC treatment produced a moderate reduction in the increased 
stiffness found in high glucose and high fatty acid treated cardiac myocytes. For the high glucose 
case, NAC treatment raised the MSD of the HG cells to levels found in the LG treated cells, with 
a subsequent reduction in the storage modulus. For the palmitic acid treated cells, NAC produced 
a more moderate increase in MSD, with a moderate decrease in storage and loss moduli. These 
data indicate that NAC may modulate the maladaptive increase in stiffness found in DC model 
CMs. 
In exploring the relationship between early stage DC hypertrophy and cell stiffness 106, 
we find the cFos levels measured with PA and NAC treatment correspond to what we found with 
cell stiffness, with PA-treatment increasing both stiffness and cFos levels, and NAC providing a 
moderate decrease in both stiffness and cFos. Additionally, high glucose treatment produced a 
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moderate increase in cFos (though not significantly) and a relatively moderate (compared to PA) 
increase in cell stiffness. However, it should also be noted that the increase in cFos found in the 





























Table 3.1. Percentage of cardiac myocytes treated with 30mM glucose compared to 5mM 
glucose control and with 0.5mM palmitic acid (PA) compared to BSA only control that 
experience diastolic abnormalities. A higher percentage of high glucose and high PA treated 
myocytes experience diastolic abnormalities compared to the controls and NAC treated CMs. 
NAC treatment reduces the presence of diastolic abnormalities in both high glucose and high 
fatty acid treated myocytes, though has little effect on control cells. In comparing treatments, 
contingency table analysis shows a significant difference (p < 0.05) in both the LG/HG and 
BSA/PA groups for diastolic dysfunction. Additionally, we confirm that the addition of NAC 
significantly reduces the significant abnormalities induced by HP treatment (p < 0.05). No 






Diastolic Dysfunction Systolic Dysfunction 
W/O NAC W/ NAC W/O NAC W/ NAC 
LG 14.3% 8.0% 0.0% 0.0% 
HG 45.9% 16.0% 2.7% 0.0% 
BSA 18.5% 16.7% 0.0% 0.0% 
PA 48.1% 18.2% 0.0% 0.0% 






Figure 3.1. Sketch of pillar array dimensions (A: top, B: side) where r is 0.75 µm, h is 5 µm, and 

















Figure 3.2: Examples of normal and dysfunctional contraction traces for individual cardiac 















      
Figure 3.3: Bar plots comparing cardiac myocyte contractile force when treated with high 
glucose (HG, A) or high palmitic acid (PA, B) concentrations with and without NAC. There is 
no significant different in force in any of the cases. 
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Figure 3.4: Measured ROS levels in CM cells treated with low glucose (LG) and high glucose 
(HG) with and without NAC (A), BSA control (BSA) and 0.5mM PA (PA) with and without 
NAC (B), and with varying concentrations of hydrogen peroxide (HP) (C).  HG treatment 
produces no significant increase in ROS levels (A), though NAC treatment leads to a significant 
decrease in ROS in both LG and HG treated CMs (* p < 0.01). PA treatment increases ROS 
levels over BSA control (B). However, NAC treatment also produces and increase in both BSA 
and PA treated CMs. The sensitivity assay (C) shows that the assay we chose does not show an 





Figure 3.5: Comparison of TXNIP levels between low (LG) and high glucose (HG) treated CMs 
with and without N-Acetyl-cysteine (NAC) as detected by Western Blot analysis (A,B). No 





Figure 3.6: cFos levels between LG and HG treated CMs with and without NAC (A,B) had a 
variable non-significant response, with HG treated CMs experiencing a non-significant increase 
in ROS levels, and NAC producing a variable response in both LG and HG treated cells. PA 
treated CMs (C,D) see a significant increase in cFos expression, suggesting the presence of 
hypertrophy in these cells, while addition of NAC reduces cFos to control levels. Finally, cFos 
levels were measured for CMs treated with varying concentrations of HP (E,F).  cFos levels were 
found to increase with increasing levels of HP, though these levels were not significantly larger 
than control except for the 50uM HP treated CMs. The results are shown as average  ± SEM. 
Statistical comparison done with one-way ANOVA with a Tukey post-test (* p < 0.05). 
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Figure 3.7: MR measures of cardiac myocytes treated with 10uM HP compared to control media. 






Figure 3.8: Plot of MSD (nm2) vs. Tau (s) (A,D), G’ (Pa) vs. frequency (Hz) (B,E), and G’’ (Pa) 
vs. frequency (Hz) (C,F) comparing properties of CM cell monolayer treated with low and high 
glucose with and without NAC.  NAC treatment produces no significance change in MSD for 
LG treated myocytes, and a significant increase in MSD at mid-range and high time lags for HG 
treated myocytes. These data suggests that NAC treatment may help modulate the increase in 





Figure 3.9: Plot of MSD (nm2) vs. Tau (s) (A,D), G’ (Pa) vs. frequency (Hz) (B,E), and  G’’ (Pa) 
vs. frequency (Hz) (C,F) comparing properties of CM monolayer treated with BSA and PA, with 
and without NAC. NAC treatment produces a significant decrease in MSD for CMs treated with 
BSA only at mid-range and high time lags, and a significant decrease in MSD for PA treated 
CMs over all time lags. These data suggests that NAC treatment may help modulate the increase 
in stiffness seen in high PA treated myocytes, but may also increase stiffness in control CMs. 
These results correlate with the cFos expression data presented in Figure 3.5. 
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Chapter 4. Summary and Future Studies 
4.1 Summary 
 The primary goal of this thesis was to measure the structural and functional properties of 
cardiac cells in an in vitro model of DC. This work was intended to provide a middle ground 
between pathway level studies, which focus on molecular level changes and in vivo studies, and 
epidemiological data, which focus on whole-heart structure and function. Specifically, we aimed 
to determine how diabetic changes, such as hyperglycemia and hyperlipidemia, affect individual 
cardiac cell mechanical properties and contractile properties. To do this, we employed 
established techniques such as atomic force microscopy (AFM), particle tracking microrheology 
(PTM), and micropillars, and established a new technique to enable the accurate measurement of 
mechanical properties of cells plated in bilayers. Here is a brief summary of major findings, 
followed by a more detailed description of the findings: 
 
1. Treatment with high glucose and high fatty-acid media increased stiffness of cardiac 
myocytes but had no significant effect on cardiac fibroblasts. This was true for CM and 
fibroblast monolayers as well as a co-cultured DC bilayer model. 
2. High glucose and high fatty-acid treatment directly contributed to diastolic dysfunction in 
CMs, but did not contribute to systolic dysfunction or affect contractile strength. 
3. High glucose treatment produced a non-significant increase in CM hypertrophy (as 
measured by common marker cFos). High fatty-acid treatment produced a significant 
increase in CM hypertrophy. 
4. Addition of ROS directly to CM media increased dysfunction and hypertrophy, but did 
not affect stiffness. 
 
 75 
5. Treatment of CMs with an antioxidant, NAC, reduced the incidence of dysfunction to 
normal levels, and modulated the increase in CM stiffness. Addition of NAC reduced 
cFos to control levels in PA-treated CMs, but produced a variable response in high 
glucose treated CMs. 
6. NAC significantly reduced ROS production in high glucose treated CMs. The TXNIP / 
TXN pathway is likely not involved in the reduction of ROS levels. 
 
4.1.1 Hyperglycemia and hyperlipidemia contribute to increased stiffness and dysfunction 
in cardiac myocytes 
 Diabetic Cardiomyopathy is primarily a disease where changes at the cellular level 
produce structural and functional changes in the myocardium that eventually manifest 
themselves in diastolic and systolic dysfunction, and eventually heart failure. Additionally, while 
many of the signs and markers of DC are known, the progression of the disease, particularly at 
the early stage is not well understood. To help elucidate this progression at the cellular level, we 
measured both the structural and contractile properties of cardiac cells under hyperglycemic and 
hyperlipidemic conditions.  
We measured the mechanical properties of cardiac cells monolayers using both atomic 
force microscopy and particle tracking microrheology. We found that high glucose treatment 
produced a significant increase in stiffness in cardiac myocytes (as measured by AFM and PTM), 
though a mixed response in viscosity across the measured frequency range (as measured by 
PTM). Hyperlipidemia (as represented by palmitic acid treatment) produced an increase in 
stiffness and viscosity across its entire frequency range. These treatments produced no changes 
in the mechanical properties of fibroblasts. These results suggest that increased myocyte stiffness 
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contributes to increased myocardial stiffness found in DC, which itself is a major contributor to 
contractile dysfunction in DC.  
 We additionally quantified functional changes in terms of contractile force and assessed 
for the presence of dysfunction. These properties were measured by plating isolated myocytes on 
micropillars arrays, where the force during CM contraction and relaxation was calculated by 
tracking the deflection of the tops of the pillars below the cells. We found that both high glucose 
and high fatty-acid conditions produce an increase in diastolic dysfunction in cardiac myocytes, 
though do not have an effect on contractile force. 
4.1.2 Development of technique employing depth resolved microscopy for cellular 
microrheology 
 One limitation of cardiac monolayers is that they generally cannot properly mimic the 
complex structural interactions that occur in the heart. We therefore developed a more 
physiologic cardiac fibroblast/myocyte bilayer model to investigate how diabetes may affect cell 
stiffness. While the passive nature of PTM makes it an ideal method for measuring the 
mechanical properties of cells in complex culture scenarios, the presence of out-of-plane beads 
can reduce the accuracy of these measurements. We therefore developed a technique, utilizing 
HiLo microscopy, to objectively determine which beads are out of plane. In a 3T3 bilayer model, 
we found that the removal of out-of-plane bead data, revealed mechanical behavior that was not 
apparent from uniform data. We then used this technique to measure the mechanical properties 
of normal and diabetic cardiac bilayers (fibroblasts plated on top of myocytes) and confirmed 
that high glucose and high fatty-acid conditions increased myocyte stiffness without significantly 
altering fibroblast stiffness. 
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4.1.3 N-Acetylcysteine reduces presence of dysfunction and modulates increase in stiffness 
in diabetic cardiac myocytes 
 Finally, we used our in vitro models to determine what role reactive oxidative species 
(ROS) has in cardiac cell stiffness and dysfunction, and whether an antioxidant, N-
Acetylcysteine (NAC), could reduce the dysfunction and increased CM stiffness found in DC. 
We found NAC treatment reduced dysfunction of both high glucose and high fatty-acid treated 
CMs. NAC significantly reduced ROS production in the low and high glucose cases, though 
appeared to increase ROS in palmitic acid experiments.  
 We additionally assessed the contribution of ROS to cell structural properties such as cell 
stiffness and hypertrophy. We found that direct addition of ROS did not directly impact CM 
mechanical properties. However, treatment of our DC in vitro model with NAC did modulate the 
increase in stiffness found in CMs. High glucose treatment produced a non-significant increase 
in the cFos levels of CMs, while addition of NAC elicited a variable response. High fatty-acid 
treatment of CMs did produce a significant increase in cFos levels, while NAC reduced cFos to 
control levels. We also found that the addition of ROS induced hypertrophy in CMs, though only 









4.2 Major limitations 
There are several limitations to consider in the context to our DC in vitro model. First, it 
should be noted that neonatal cardiac myocytes are not an ideal model for DC, as the onset of 
diabetes (particularly T2DM) typically occurs post-infancy 128, 129. However, neonatal CMs 
remain a common in vitro cardiac model, as they are significantly simpler to plate and culture 
than adult CMs or clonal HL-1 cells. Neonatal CMs also retain their contractile properties, which 
are lost in clonal lines such as H9C2s. We additionally found it necessary to simplify our cell 
model, as we utilize relatively complex and novel techniques (such as bilayer microrheology and 
micropillars) to measure the biomechanical properties of cardiac cells.  
We also note that we chose a relatively short-term exposure to high glucose (48 hours) 
and high fatty acid (24 hours) environments. Due to the chronic nature of diabetes, the diabetic 
heart is generally exposed to hyperglycemic and hyperlipidemic conditions over a much larger 
time scale. However, we found that after 3 days culture (from plating), the growth of cardiac 
fibroblasts would lead to the bunching together of the CMs, substantially affecting their 
morphology. Therefore, all data was taken 3 days from culture.  
 Another limitation lies in our choice of endocytosis as the method for introducing probes 
to the cells for our PTM study. While endocytosis is not an ideal method due to the possibility of 
active probe motion, other current methods such as microinjection and blast injection can 
significantly damage the cell 107, 130. As myocytes can not be readily re-plated, and are sensitive 
to disruptions to their monolayer, endocytosis provides the best means to accurately measure the 
mechanical properties of healthy myocytes. 
It should also be noted that the thresholding process for HiLo-based optical sectioning 
technique (used for bilayer microrheology study) is imperfect. As a result, one has to be very 
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careful in using this method to characterize viscoelastic properties. All beads within the imaging 
plane were likely preserved; however, ~10% of the beads out-of-plane were included. In the 
cases presented here, the inclusion of 10% of out-of-plane probes likely did not significantly 
affect our results. For example, for the 3T3 bilayer study, imaging the bottom layer included 
24% out-of-plane beads. Thus, out of every hundred beads imaged, 2-3 out-of-plane beads are 
included, after HiLo-based thresholding. Approximately 40% of the imaged beads were out-of-
plane in the top layer images. Thus, out of every hundred beads imaged, 4-5 beads from out-of-
plane regions will remain after HiLo-based thresholding. Since this represents less than 8% of all 
beads analyzed in each layer, the contribution of these out-of-plane beads are not likely to be 
significant, especially since they are unlikely far from the imaging plane. However, if one were 
to perform a study where there were high numbers of out-of-plane beads compared to in-plane 
beads, the contribution of out-of-plane beads may render the analysis incomplete or inaccurate. It 
should be noted that the threshold determined from the polyacrylamide gel may actually remove 
a higher percentage of out-of-plane beads in the cell bilayer than in the gel, as the out-of-plane 
bead intensity may drop more in the cell bilayer compared to the diminished scattering 
conditions of the gel. The technique developed in this study will allow for quantitative 
measurements of the viscoelastic properties of cells, and perhaps tissues, in more physiologic 
cell constructs. Additionally, this technique can also be used to enhance conventional in vitro 2D 
PTM experiments, by allowing for the study of subcellular planar sections, to assess apical 
versus basal properties, for example. However, it should be noted that there is a limit to the 
information we can gain from HiLo processing due to the presence of image distortion. This is 
especially true of very thick or opaque samples. 
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 Finally, it should be noted that the results of the micropillar data is limited by our use of 
single isolated myocytes as opposed to more physiologic monolayers. While other studies have 
measured the traction force of cell-doublets (measuring cell-cell adhesion force) 102 and cell 
sheets 131, no studies have specifically focused on cardiac myocytes. We believe it is necessary to 
establish these techniques with relatively simple cardiac models before exploring disease models 
such as DC. 
4.3 Future studies 
Here we propose several studies that could follow from the findings of this thesis. 
4.3.1 Determine if diabetes increases cardiac myocyte stiffness in in vitro model 
 High glucose and high fatty-acid conditions lead to an increased stiffness in isolated 
cardiac myocytes. However, it is currently unknown whether this result carries over to diabetic 
animal models or patients with DC. Many groups have used rodent diabetes model that mimics 
many of the signs found in human DC 47, 132. On creating the model, it would be possible to 
isolate the cells at various stages in disease development, to determine if diabetes increases 
myocyte stiffness. Using this model, it would also be possible to assess for collagen growth at 
these stages (through histology), assess overall myocardial tissue stiffness, and measure cardiac 
functional properties such as heart rate, blood pressure, and contraction and relaxation rates. 
Through this method we could better establish the early-stage progression of DC. 
4.3.2 Use functional in vitro model to explore other pathways that produce dysfunction and 
other treatment options 
 In this thesis, we focused on the impact of oxidative damage on the functional properties 
of cardiac myocytes. It is a natural extension to use this model to assess the contribution of other 
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signs of DC, such as calcium mishandling, to cardiac dysfunction, or assess the efficacy of 
various molecular targets.  
4.3.3 Expand use of HiLo-PTM technique for embedded cells and in vivo 
 While the HiLo-based optical section technique was utilized in this study to measure the 
mechanical properties of a cell bilayer, the next step is to use the technique to measure the 
properties of cells in increasingly physiologic culture scenarios such as in three-dimensional 
tissue contracts. This technique could also be used to measure the mechanical properties of 
myocytes in vivo. This could be done by either using blast injection to forcibly embed 
fluorescent probes inside living tissue, or by adapting the technique to be used with endogenous 
subcellular markers.  
4.4 Conclusion 
 The data presented here has significant implications for the current understanding and 
future treatment of DC. In general, the understanding of the early stage pathogenesis of DC has 
been confined to changes on the biochemical and pathway levels. However, the results presented 
in this study indicate that early-stage DC pathogenesis may also involve changes on the 
biomechanical level, with 24-48 hour treatments with high glucose and high fatty-acid media 
producing a significant increase in myocyte stiffness as well as in the occurrence of diastolic 
dysfunction. 
 In the context of DC, an increase in myocardial stiffness is commonly found in the 
middle to later stages of the disease, and is generally associated with an increase in myocardial 
fibrosis. Indeed, while an increase in myocyte resting tension has been associated with DC, this 
has only been measured in the end stages of diabetic heart failure 106. The in vitro model 
developed here indicates that this increase in stiffness may actually occur very early in DC 
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pathogenesis, possibly contributing to early stage subclinical diastolic dysfunction as well as 
increased overall myocardial stiffness at early and possibly later stages of the disease.  
In addition, we found that short-term treatments with high fatty acid, high glucose, and 
high ROS media significantly increased the prevalence of diastolic dysfunction in cardiac 
myocytes. While previous DC studies have suggested that ROS and diabetic conditions can 
induce dysfunction, this is the first study that establishes this link directly, and establishes that 
these functional changes can occur on a very short timescale. Overall, these results suggest that 
the timescale from the onset of diabetes to the onset of mechanical and functional changes in the 
myocardium may be much shorter than has been hypothesized from current clinical data 52, 103. 
While it is currently unclear what affect these early-stage changes have on overall DC 
pathogenesis, it is revealing that major results found in this study (increased myocardial stiffness 
and diastolic dysfunction) are clinical hallmarks of the disease. 
 Finally, in the context of DC treatment, this study establishes the use of N-Acetyl-
Cysteine (NAC) as a means for reducing glucose / fatty-acid induced myocyte stiffening, as well 
diastolic dysfunction. The results presented here, in conjunction with the promising results of 
Xia et al.’s in vivo DC model suggest the need of further testing of NAC (and potentially other 
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